ATA242288A - Dosierungsform für die behandlung kardiovaskulärer erkrankungen - Google Patents

Dosierungsform für die behandlung kardiovaskulärer erkrankungen

Info

Publication number
ATA242288A
ATA242288A AT0242288A AT242288A ATA242288A AT A242288 A ATA242288 A AT A242288A AT 0242288 A AT0242288 A AT 0242288A AT 242288 A AT242288 A AT 242288A AT A242288 A ATA242288 A AT A242288A
Authority
AT
Austria
Prior art keywords
dosage
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
AT0242288A
Other languages
English (en)
Other versions
AT402689B (de
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ATA242288A publication Critical patent/ATA242288A/de
Application granted granted Critical
Publication of AT402689B publication Critical patent/AT402689B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT0242288A 1987-10-02 1988-09-30 Dosierungsform für die behandlung kardiovaskulärererkrankungen AT402689B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (2)

Publication Number Publication Date
ATA242288A true ATA242288A (de) 1996-12-15
AT402689B AT402689B (de) 1997-07-25

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0242288A AT402689B (de) 1987-10-02 1988-09-30 Dosierungsform für die behandlung kardiovaskulärererkrankungen

Country Status (22)

Country Link
US (1) US4816263A (de)
JP (1) JP2590235B2 (de)
KR (1) KR950010151B1 (de)
AT (1) AT402689B (de)
AU (1) AU615215B2 (de)
BE (1) BE1001101A5 (de)
CA (1) CA1317550C (de)
CH (1) CH677609A5 (de)
DE (1) DE3833282C2 (de)
DK (1) DK175564B1 (de)
ES (1) ES2011120A6 (de)
FI (1) FI92554C (de)
FR (1) FR2622798B1 (de)
GB (1) GB2210266B (de)
IE (1) IE61862B1 (de)
IT (1) IT1234215B (de)
LU (1) LU87351A1 (de)
NL (1) NL194748C (de)
NO (1) NO176466C (de)
PT (1) PT88618B (de)
SE (1) SE503471C2 (de)
ZA (1) ZA887362B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
PT1404324E (pt) * 2001-06-11 2008-03-05 Xenoport Inc Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
AU2003297909A1 (en) * 2002-12-11 2004-06-30 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
EP2354120A1 (de) 2003-08-20 2011-08-10 XenoPort, Inc. Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP1670451A4 (de) * 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
ES2345784T3 (es) * 2005-06-20 2010-10-01 Xenoport, Inc. Profarmacos de aciloxialquilcarbamato del acido tranexamico y uso de los mismos.
AU2006261788B2 (en) 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
KR20090031519A (ko) 2006-05-26 2009-03-26 파마코포어, 인크. 페놀계 오피오이드의 제어 방출
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EA200970487A1 (ru) * 2006-12-08 2009-12-30 Ксенопорт, Инк. Применение пролекарств аналогов гамк для лечения заболеваний
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
JP2018534269A (ja) 2015-10-01 2018-11-22 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に抵抗性のポリサブユニットオピオイドプロドラッグ
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2018170465A1 (en) 2017-03-17 2018-09-20 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
US4816263A (en) 1989-03-28
GB2210266A (en) 1989-06-07
NO884259L (no) 1989-04-03
SE8803486L (sv) 1989-04-03
AU2293888A (en) 1989-04-06
LU87351A1 (fr) 1989-04-06
DK545088D0 (da) 1988-09-29
FR2622798B1 (fr) 1993-10-15
ES2011120A6 (es) 1989-12-16
FI884526L (fi) 1989-04-03
CA1317550C (en) 1993-05-11
DK545088A (da) 1989-04-03
NL194748C (nl) 2003-02-04
SE8803486D0 (sv) 1988-09-30
IE882960L (en) 1989-04-02
NL8802401A (nl) 1989-05-01
NO884259D0 (no) 1988-09-27
JP2590235B2 (ja) 1997-03-12
FI92554B (fi) 1994-08-31
PT88618A (pt) 1989-07-31
AU615215B2 (en) 1991-09-26
BE1001101A5 (fr) 1989-07-11
IE61862B1 (en) 1994-11-30
AT402689B (de) 1997-07-25
FI92554C (fi) 1994-12-12
FI884526A0 (fi) 1988-09-30
ZA887362B (en) 1989-06-28
GB8822852D0 (en) 1988-11-02
DK175564B1 (da) 2004-12-06
NO176466B (no) 1995-01-02
DE3833282C2 (de) 1997-02-13
PT88618B (pt) 1993-07-30
SE503471C2 (sv) 1996-06-24
GB2210266B (en) 1991-07-24
DE3833282A1 (de) 1989-04-20
KR950010151B1 (ko) 1995-09-11
IT8867880A0 (it) 1988-09-30
NO176466C (no) 1995-04-12
FR2622798A1 (fr) 1989-05-12
IT1234215B (it) 1992-05-06
CH677609A5 (de) 1991-06-14
KR890006218A (ko) 1989-06-12
JPH01113316A (ja) 1989-05-02
NL194748B (nl) 2002-10-01

Similar Documents

Publication Publication Date Title
ATA242288A (de) Dosierungsform für die behandlung kardiovaskulärer erkrankungen
DE3585981D1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
DE3775805D1 (de) Arzneimittel zur behandlung periodontaler erkrankungen.
ATE235906T1 (de) Substituierte phenylpyrimidine derivate, für die behandlung oder prevention von zns-erkrankungen
IT8322855A0 (it) Composizione farmaceutica per la cura delle arteriopatie periferiche.
BG94738A (bg) Използване на разтвор на йод за лечение на заболявания, свързани с йодна недостатъчност
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
FI891986A7 (fi) Farmaseuttiset koostumukset psoriasiksen hoitoon
DE3687692D1 (de) Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
ATE11013T1 (de) Heilmittelzusammensetzungen zur behandlung der haut.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
IT1210935B (it) Composizione farmaceutica per il trattamento di malattie cardiovascolari.
IT1195940B (it) Procedimento per la produzione di interferone da geni umani
DE3866653D1 (de) Zusammensetzung fuer die behandlung der epidermis.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
IT1224741B (it) Dispositivo per il trattamento delle malattie delle gengive
IT8212678A0 (it) Preparato per il trattamento del l acne
IT1209508B (it) Nuovi medicinali per il trattamento di malattie cardiache.
IT8249656A0 (it) Preparato anti-infiammatorio nonsteroideo, per il trattamento delle affezioni artroreumatiche e metodo per la sua preparazione
IT8248329A0 (it) Tienil e benzotienil-terz.-butilamminofenossipropanoli per il trattamento di affezioni cardiovascolari
IT8219330A0 (it) Composto medicinale per il trattamento di malattie di cuore.
IT8321614A0 (it) Medicina per il trattamento di affezione neoplastica.
RO77471A2 (ro) Produs destinat tratamentului nozemozei la albine
IT1212555B (it) Composizione a base di dobesilato di calcio per il trattamento di malattie cardiache
DE68905479D1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.

Legal Events

Date Code Title Description
ELA Expired due to lapse of time